The FDA did NOT grant full approval to the Pfizer

New Post Public Reply Private Reply Replies (1) Message Board
energy_wave
1,569
The FDA did NOT grant full approval to the Pfizer shots

Quote:
August 26, 2021

By Carl Schwitzer

You may have heard that the Pfizer-BioNTech COVID-19 shot received FDA approval this past Monday. Politicians, national health officials, and journalists are breathless with excitement about how this approval will finally induce the remaining "vaccine-hesitant" into stepping forward to receive their jab. The FDA even has a press release on its website about it.

There's just one problem.

If you read the actual letters that the FDA sent to Pfizer on August 23, 2021, you'll see that the FDA did no such thing. In the sense that the term "FDA approval" is generally understood, this drug is not approved by the FDA. It is still under EUA (Emergency Use Authorization). It is still an experimental drug.

The FDA sent two letters. The first one was a letter of BLA (Biologics License Application) approval, and the second was a letter of EUA extension to COMIRNATY.

The BLA approval letter approves Pfizer's application for a license to label its COVID-19 drug with the brand name COMIRNATY. This letter also spells out the terms and requirements for nine additional clinical trials over five years, and yearly status reports, to study the acknowledged occurrences of myocarditis and pericarditis that have followed the administering of the Pfizer shots. This license to label and manufacture is not a full approval of the drug, which clearly is still subject to many years of clinical trials.

The EUA extension letter extends the term of the EUA for the current drug and authorizes (licenses) the experimental use of the brand-name drug COMIRNATY. In the first paragraph on page 2, this letter references the license approval letter. In the second paragraph on page 2, the August 12 EUA is re-issued to include the name-branded drug in the emergency use authorization, and to add "language regarding warnings and precautions related to myocarditis and pericarditis." In the last paragraph on page 4, the EUA nature of the drugs is re-iterated, and COMIRNATY is additionally authorized for use for individuals aged 12 through 15 years.

The mRNA gene therapy shots are still experimental. Mandating them is still wrong — by a wide variety of ethical standards.

Dr. Meryl Nass, M.D. found the truths that the FDA buried in the blather of these letters and offers a theory about why it was done this way. The drug-manufacturers were granted immunity from liability for the drugs produced under the EUAs. The granting of the license re-applies the customary liability for injury and death caused by the product. Pfizer, the health officials, and the politicians get to take a fictitious victory lap for the "approval," while Pfizer-BioNTech continues to stealthily enjoy immunity from product liability because there are many millions of the unlicensed doses on the shelves and in the manufacturing pipeline that will be administered first. The licensed version will not arrive on shelves or be jabbed into arms for many months to come.

Of great concern, considering the factual content of the FDA EUA letters to Pfizer, is the breezy way the press release on the FDA website repeatedly uses the words "approve" and "approval" in reference to the Pfizer drug. If only there were a word for intentionally saying things to the public that do not match reality...

COMIRNATY seems like an unusual name for anything, much less a cutting-edge-technology gene therapy. Out of idle curiosity, I ran the name through an anagram solver. For a result, it gave TIROMANCY, which is divination or prophecy by examining how curds form during the coagulation of cheese. How apropos. That's something I'm willing to try for forecasting the results of the next election!
By Carl Schwitzer

You may have heard that the Pfizer-BioNTech COVID-19 shot received FDA approval this past Monday. Politicians, national health officials, and journalists are breathless with excitement about how this approval will finally induce the remaining "vaccine-hesitant" into stepping forward to receive their jab. The FDA even has a press release on its website about it.

There's just one problem.

If you read the actual letters that the FDA sent to Pfizer on August 23, 2021, you'll see that the FDA did no such thing. In the sense that the term "FDA approval" is generally understood, this drug is not approved by the FDA. It is still under EUA (Emergency Use Authorization). It is still an experimental drug.

The FDA sent two letters. The first one was a letter of BLA (Biologics License Application) approval, and the second was a letter of EUA extension to COMIRNATY.

The BLA approval letter approves Pfizer's application for a license to label its COVID-19 drug with the brand name COMIRNATY. This letter also spells out the terms and requirements for nine additional clinical trials over five years, and yearly status reports, to study the acknowledged occurrences of myocarditis and pericarditis that have followed the administering of the Pfizer shots. This license to label and manufacture is not a full approval of the drug, which clearly is still subject to many years of clinical trials.

The EUA extension letter extends the term of the EUA for the current drug and authorizes (licenses) the experimental use of the brand-name drug COMIRNATY. In the first paragraph on page 2, this letter references the license approval letter. In the second paragraph on page 2, the August 12 EUA is re-issued to include the name-branded drug in the emergency use authorization, and to add "language regarding warnings and precautions related to myocarditis and pericarditis." In the last paragraph on page 4, the EUA nature of the drugs is re-iterated, and COMIRNATY is additionally authorized for use for individuals aged 12 through 15 years.

The mRNA gene therapy shots are still experimental. Mandating them is still wrong — by a wide variety of ethical standards.

Dr. Meryl Nass, M.D. found the truths that the FDA buried in the blather of these letters and offers a theory about why it was done this way. The drug-manufacturers were granted immunity from liability for the drugs produced under the EUAs. The granting of the license re-applies the customary liability for injury and death caused by the product. Pfizer, the health officials, and the politicians get to take a fictitious victory lap for the "approval," while Pfizer-BioNTech continues to stealthily enjoy immunity from product liability because there are many millions of the unlicensed doses on the shelves and in the manufacturing pipeline that will be administered first. The licensed version will not arrive on shelves or be jabbed into arms for many months to come.

Of great concern, considering the factual content of the FDA EUA letters to Pfizer, is the breezy way the press release on the FDA website repeatedly uses the words "approve" and "approval" in reference to the Pfizer drug. If only there were a word for intentionally saying things to the public that do not match reality...

COMIRNATY seems like an unusual name for anything, much less a cutting-edge-technology gene therapy. Out of idle curiosity, I ran the name through an anagram solver. For a result, it gave TIROMANCY, which is divination or prophecy by examining how curds form during the coagulation of cheese. How apropos. That's something I'm willing to try for forecasting the results of the next election!



https://www.americanthinker.com/blog/2021/08/...shots.html
big-wave_surfing_01.jpg
Scroll down for more posts ▼

Top 10 Most Recent News Articles

PCOS/PMOS Symposium 2026: A Game-Changer for Health

Updated Category News Views 3

A Fiery Gathering for Future PCOS/PMOS Progress Kicking off in Boston on September 19, the PCOS/PMOS Awareness Symposium 2026 isn't your typical chalk-and-talk affair. This gathering is a powerhouse meld of patients, experts, and the policy world all under one roof. You think that's easy to pull off? Not a chance. It's cemented by the PCOS Challenge group and Brigham's...

Continue Reading
BD&J Shines in Elite 2026 Legal Ranking for California

Updated Category News Views 1

A Rare Nod from Chambers and Partners Now and then, the legal spotlight lands in places you don't quite expect. This time, it’s BD&J—a stalwart of the personal injury field—grabbing the limelight right from under the noses of California's Big Law giants. This firm has been pegged as a top contender in the 2026 Chambers and Partners Spotlight Guide. And let me tell...

Continue Reading
Steve McCurry's Mastery Captured in 'Adagio' Exhibition

Updated Category News Views 1

The Reverie of Real Imagery It might be time to give New York a spot on your calendar. Adagio, the latest exhibition at Leica Gallery, reveals the enduring magic of Steve McCurry's lens. Running from September 10th to October 18th, 2026, this event does more than showcase photos—it crafts an experience of human connection. A Dance with History This isn’t just a walk...

Continue Reading
Big Growth Expected in Data Handling Units Market

Updated Category News Views 1

Taking Stock of the Data Center Cooling Evolution Imagine a world where data centers balloon like mushrooms after rain. That's exactly what's happening. The data center air handling units market is on a growth spurt, forecasted to blow up from $4.00 billion in 2026 to a hefty $6.70 billion by 2032. Thank the sky-high demand driven by an ever-growing appetite for AI, cloud...

Continue Reading
Battery Network Boosts Services with New VP Hire

Updated Category News Views 3

New Leadership at The Battery Network News from the battery world, folks—The Battery Network has nabbed Adam Greenberg as their new Vice President of Services and Solutions. If you’re not familiar, The Battery Network ain’t just your run-of-the-mill nonprofit; these folks are the backbone of battery recycling across the States. Previously known as Call2Recycle, this...

Continue Reading
Exploring Denture to Implant Solutions with Dr. Miller

Updated Category News Views 1

The Changing Face of Tooth Replacement Let's dive into teeth. We're talking dentures, implants, and the rest of the gang that live in the world of full mouth replacements. Dr. Christopher Glenn Miller’s insights shared with HelloNation zero in on the evolution of tooth replacement options. Gone are the days of clunky dentures being your only shot. From sucking gum to...

Continue Reading
SB Energy Files to Go Public, Eyes Nasdaq Listing

Updated Category News Views 2

SB Energy Taking IPO Leap There's a fresh face aiming to play with the big dogs in the stock market: SB Energy, Inc. They've gone ahead and tossed their hat into the IPO ring, filing a registration with the SEC. Now, they're looking to claim a slice of the Nasdaq with a ticker of "SBE." It's a gutsy move, especially given this rollercoaster of a market—one minute you're...

Continue Reading
Syra Health Expands Public Health Wellness Initiative

Updated Category News Views 1

Wellness Programs in Public Health: A Necessary Evolution Syra Health and Wake County Public Health are kicking off a renewed push for wellness with their Wellness S.P.A. 2.0 initiative. This isn't just a fancy rehash of their earlier project. Nope, it's a full-on effort to support those on the frontline of public health, those folks bearing the brunt of complex...

Continue Reading
Nexio's New Campus Ignites Truck Production Ambitions

Updated Category News Views 3

Big Moves into the Big Truck Arena Nexio Power is making significant strides in making heavy trucks powered by propane a reality. By securing a massive 77-acre campus in Anderson, Texas, the company is setting the stage for immediate production capabilities. It's not often you see a company like Nexio pulling the rug out from others so quietly but effectively. This campus...

Continue Reading
ZERO Fresh Start: RAVEN2's New Era Begins Sept 15

Updated Category News Views 0

What's the Big Deal with ZERO? Alright, so here we go, folks—Netmarble's strapping in with their latest server for RAVEN2, and it's called ZERO. Ever heard of fresh starts? ZERO is exactly that. This isn't your usual server shuffle. Lads and ladies who've felt the grind’ll tell you, ZERO's introducing a slew of changes you might want to sit up for. Pre-registration's...

Continue Reading

Top 5 Most Recently Viewed Articles

Central Iron Ore Limited Welcomes New Director with Expertise

Updated Category News Views 155

Central Iron Ore Limited Expands Board with Mining Expert Central Iron Ore Limited (TSX-V: CIO) is excited to announce a significant addition to our board of directors. Mr. Paul Richardson joins us with a wealth of knowledge and experience in the mining industry, marking a pivotal step in our growth trajectory. Rich Experience in Mining Mr. Richardson brings over 43 years...

Continue Reading
NexGold Secures C$10 Million in Recent Private Placement Deal

Updated Category News Views 175

NexGold Achieves Major Financing Milestone NexGold Mining Corp. (TSXV: NEXG; OTCQX: NXGCF) has successfully completed a significant private placement valued at C$10 million, marking a pivotal advancement for the company. This financing is set to bolster the development of its gold assets located in Canada and Alaska. Details of the Private Placement In this latest...

Continue Reading
Transforming Interaction: AI and AR Technology on the Rise

Updated Category News Views 95

AI and AR: A New Era in Interaction As technology evolves rapidly, the integration of artificial intelligence (AI) and augmented reality (AR) is revolutionizing the way humans interact with computers. With breakthroughs in multimodal perception and spatial computing, AI glasses are set to become a pivotal technology. These advancements forecast significant growth,...

Continue Reading
Shell plc Enhances Share Buy-Back Strategy for Investors

Updated Category News Views 175

Shell plc's Commitment to Shareholder Value In a noteworthy move for investors, Shell plc recently undertook significant transactions in its own shares to enhance shareholder value. These share purchases play a critical role in the company's ongoing strategy to manage its capital and improve stock performance. Details of Recent Share Purchases The company announced the...

Continue Reading
Continuous Commitment to Shareholder Value by One Liberty

Updated Category News Views 71

One Liberty Properties Declares Quarterly Dividend – Increased or Maintained Dividend for Over 30 Consecutive Years – One Liberty Properties, Inc. (NYSE: OLP) has made an exciting announcement regarding the latest quarterly dividend. With a focus on consistent shareholder value, the Board of Directors declared a dividend of $0.45 per share. This payment signifies a...

Continue Reading